Catalytically Generated Ferrocene-Containing Guanidines as Efficient Precursors for New Redox-Active Heterometallic Platinum(II) Complexes with Anticancer Activity

Boron Complexes with Propiolamidinato Ligands: Synthesis, Structure, and Photophysical Properties

Two series of boron derivatives with propiolamidinato ligands, [BPh2{C(C≡CAr)(NR)2}] (Ar = Ph, p-MeOPh, p-FPh, p-Me2NPh, or phen; R = iPr or p-tolyl), were synthesized and structurally characterized. The corresponding propiolamidine (or propargylamidine) proligands have been obtained through sustainable methods. One is the catalytic hydroalkynylation of diisopropylcarbodiimide with different terminal alkynes, using simple ZnEt2 as a precatalyst. Alternatively, to obtain propiolamidines with aromatic groups on the nitrogen atoms, the formation of lithiated derivatives of terminal alkynes by reaction with n-BuLi in air and at room temperature, and subsequent addition to the di-p-tolylcarbodiimide, under the same conditions and using 2-MeTHF as a sustainable solvent, has been used for the first time. After reaction with BPh3, the corresponding boron amidinates were obtained, which are emissive in the solution state. The influence of the different substituents introduced into the ligands on the photophysical properties of the boron compounds has been studied. One of the obtained compounds can be used as a ratiometric fluorescent pH sensor in the acidic range.

Synthetic and natural guanidine derivatives as antitumor and antimicrobial agents: A review

Guanidines are fascinating small nitrogen-rich organic compounds, which have been frequently associated with a wide range of biological activities. This is mainly due to their interesting chemical features. For these reasons, for the past decades, researchers have been synthesizing and evaluating guanidine derivatives. In fact, there are currently on the market several guanidine-bearing drugs. Given the broad panoply of pharmacological activities displayed by guanidine compounds, in this review, we chose to focus on antitumor, antibacterial, antiviral, antifungal, and antiprotozoal activities presented by several natural and synthetic guanidine derivatives, which are undergoing preclinical and clinical studies from January 2010 to January 2023. Moreover, we also present guanidine-containing drugs currently in the market for the treatment of cancer and several infectious diseases. In the preclinical and clinical setting, most of the synthesized and natural guanidine derivatives are being evaluated as antitumor and antibacterial agents. Even though DNA is the most known target of this type of compounds, their cytotoxicity also involves several other different mechanisms, such as interference with bacterial cell membranes, reactive oxygen species (ROS) formation, mitochondrial-mediated apoptosis, mediated-Rac1 inhibition, among others. As for the compounds already used as pharmacological drugs, their main application is in the treatment of different types of cancer, such as breast, lung, prostate, and leukemia. Guanidine-containing drugs are also being used for the treatment of bacterial, antiprotozoal, antiviral infections and, recently, have been proposed for the treatment of COVID-19. To conclude, the guanidine group is a privileged scaffold in drug design. Its remarkable cytotoxic activities, especially in the field of oncology, still make it suitable for a deeper investigation to afford more efficient and target-specific drugs.

Metal-Based Complexes as Potential Anti-cancer Agents

Metal based therapy is no new in biomedical research. In early days the biggest limitation was the inequality among therapeutical and toxicological dosages. Ever since, Barnett Rosenberg discovered cisplatin, a new era has begun to treat cancer with metal complexes. Platinum complexes such as oxaliplatin, cisplatin, and carboplatin, seem to be the foundation of metal/s-based components to challenge malignancies. With an advancement in the biomolemoecular mechanism, researchers have started developing non-classical platinum-based complexes, where a different mechanistic approach of the complexes is observed towards the biomolecular target. Till date, larger number of metal/s-based complexes was synthesized by overhauling the present structures chemically by substituting the ligand or preparing the whole novel component with improved cytotoxic and safety profiles. Howsoever, due to elevated accentuation upon the therapeutic importance of metal/s-based components, a couple of those agents are at present on clinical trials and several other are in anticipating regulatory endorsement to enter the trial. This literature highlights the detailed heterometallic multinuclear components, primarily focusing on platinum, ruthenium, gold and remarks on possible stability, synergism, mechanistic studies and structure activity relationships.

Has Ferrocene Really Delivered Its Role in Accentuating the Bioactivity of Organic Scaffolds?

Ferrocene is an important structural core in bioorganometallic chemistry because of its inherent stability, excellent redox properties, and low toxicity. Ferroquine and ferrocifen are two of the most notable contributions of ferrocene to medicinal chemistry with remarkable antimalarial and anticancer properties. The improved medicinal properties of these drug candidates highlight the impact that ferrocene can have on the molecular and biological properties of the bioactive compounds. In this Perspective, we investigate the scope and limitations of ferrocene incorporation into organic compounds/natural products on their mode of action and biological activities. We have also discussed the detailed role of ferrocene modifications in influencing the anticancer, antimalarial, and antimicrobial properties of various bioactive moieties to design safer and promising ferrocene-based drugs.

Design, Synthesis, and in vitro Evaluation of Tubulin-Targeting Dibenzothiazines with Antiproliferative Activity as a Novel Heterocycle Building Block

We prepared a series of free NH and N-substituted dibenzonthiazines with potential anti-tumor activity from N-aryl-benzenesulfonamides. A biological test of synthesized compounds (59 samples) was performed in vitro measuring their antiproliferative activity against a panel of six human solid tumor cell lines and its tubulin inhibitory activity. We identified 6-(phenylsulfonyl)-6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide and 6-tosyl-6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide as the best compounds with promising values of activity (overall range of 2-5.4 μM). Herein, we report the dibenzothiazine core as a novel building block with antiproliferative activity, targeting tubulin dynamics.

Copper-Catalyzed Single C-H Amination of 8-Aminoquinoline-Directed Ferrocenes

An unprecedented copper-catalyzed C-H monoamination of ferrocenes directed by an 8-aminoquinoline amide directing group is described. This reaction proceeds in the presence of a catalytic amount of copper catalyst with both cyclic and acyclic amines to afford the various aminoferrocenes. The C-H amination of ortho-substituted ferroceneamides was also achieved, enabling rapid access to multisubstituted ferrocenes that are useful for developing new functional molecules.

A 2-(benzothiazol-2-yl)-phenolato platinum(II) complex as potential photosensitizer for combating bacterial infections in lung cancer chemotherapy†

Cancer and antibiotic resistance are two global health threats that usually hamper clinical chemotherapeutic efficacy. Particularly for lung cancer, bacterial infections frequently arise thereby complicating the course of cancer treatment. In this sense, three new neutral luminescent cycloplatinated(II) photosensitizers of the type [Pt(dmba)(L)] (dmba = N,N-dimethylbenzylamine-κN,κC; L = 2-(benzo[d]oxazol-2-yl)-phenolato-κN,κO1, 2-(benzo[d]thiazol-2-yl)-phenolato-κN,κO2, and 2-(1-methyl-1H-benzo[d]imidazole-2-yl)phenolato-κN,κO3) have been characterized and developed to potentially eliminate both resistant bacteria and lung cancer cells. The phototherapeutic effects of complex 2 have been evaluated using low doses of blue light irradiation. Complex 2 exerted promising photoactivity against pathogenic Gram-positive bacteria strains of clinical interest, displaying a phototoxic index (PI) of 15 for methicillin-resistant Staphylococcus aureus, one of the major microorganisms predominating lung infections. Likewise, the anticancer activity of 2 was also increased upon light irradiation in human lung A549 cancer cells (PI = 36). Further in vitro experiments with this platinum(II) complex suggest that ROS-generating photodynamic reactions were involved upon light irradiation, thus providing a reasonable mechanism for its dual anticancer and antibacterial activities.

Synthesis and study of Fe → Pd interactions in unsymmetric Pd(ii) complexes with phosphinoferrocene guanidine ligands

Readily available phosphinoferrocene guanidines coordinate Pd(ii) as P,N-chelating or κ3P,N,Fe-bound ligands. As the latter, they give rise to the first donor-asymmetric complexes featuring Fe-Pd dative bonds, which were studied using direct (spectroscopic and electrochemical) methods and theoretical (DFT) approaches.

Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships

Cancer is one of the most fatal threatens to human health throughout the world. The major challenges in the control and eradication of cancers are the continuous emergency of drug-resistant cancer and the low specificity of anticancer agents, creating an urgent need to develop novel anticancer agents. Organometallic compounds especially ferrocene derivatives possess remarkable structural and mechanistic diversity, inherent stability towards air, heat and light, low toxicity, low cost, reversible redox, ligand exchange, and catalytic properties, making them promising drug candidates for cancer therapy. Ferrocifen, a ferrocene-phenol hybrid, has demonstrated promising anticancer properties on drug-resistant cancers. Currently, Ferrocifen is in pre-clinical trial against cancers. Obviously, ferrocene moiety is a useful template for the development of novel anticancer agents. This review will provide an overview of ferrocene-containing hybrids with potential application in the treatment of cancers covering articles published between 2010 and 2020. The mechanisms of action, the critical aspects of design and structure-activity relationships are also discussed.

Aluminum complexes with new non-symmetric ferrocenyl amidine ligands and their application in CO2 transformation into cyclic carbonates

A set of alkyl aluminum complexes supported by non-symmetric ferrocenyl amidine ligands were used as catalysts for the preparation of cyclic carbonates from epoxides and carbon dioxide using Bu₄NI as a co-catalyst.

The crystal structure of bis(ferrocenecarboxylato-κ2 O,O′)bis[4-(dimethylamino)pyridine-κN]copper(II) — acetonitrile(1/2), C40H44CuO4Fe2N6

C40H44CuO4Fe2N6, triclinic, P1̄ (no. 2), a = 7.4758(4) Å, b = 7.7447(5) Å, c = 16.2929(10) Å, α = 87.111(2)°, β = 85.196(2)°, γ = 89.736(2)°, V = 938.82(10) Å3, Z = 1, R gt(F) = 0.0672, wR ref(F 2) = 0.1316, T = 150(2) K.

Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer

Following promising recent in vitro and in vivo studies of the anticancer efficacies of heterometallic titanocene-gold chemotherapeutic candidates against renal cancer, we report here on the synthesis, characterization, stability studies and biological evaluation of a new titanocene complex containing a gold-triethylphosphane fragment [(η-C₅H₅)₂TiMe(μ-mba)Au(PEt₃)] (4) Titanofin. The compound is more stable in physiological fluid than those previously reported, and it is highly cytotoxic against a line of human clear cell renal carcinoma. We describe here preliminary mechanistic data for this compound and previously reported [(η-C₅H₅)₂TiMe(μ-mba)Au(PPh₃)] (2) Titanocref which displayed remarkable activity in an in vivo mouse model. Mechanistic studies were carried out in the human clear cell renal carcinoma Caki-1 line for the bimetallic compounds [(η-C₅H₅)₂TiMe(μ-mba)Au(PR₃)] (PR₃ = PPh₃2 Titanocref and PEt₃4 Titanofin), the two monometallic gold derivatives [Au(Hmba)(PR₃)] (PR₃ = PPh₃1 cref; PEt₃3 fin), titanocene dichloride and Auranofin as controls. These studies indicate that bimetallic compounds Titanocref (2) and Titanofin (4) are more cytotoxic than gold monometallic derivatives (1 and 3) and significantly more cytotoxic than titanocene dichloride while being quite selective. Titanocref (2) and Titanofin (4) inhibit migration, invasion, and angiogenic assembly along with molecular markers associated with these processes such as prometastatic IL(s), MMP(s), TNF-α, and proangiogenic VEGF, FGF-basic. The bimetallic compounds also strongly inhibit the mitochondrial protein TrxR often overexpressed in cancer cells evading apoptosis and also inhibit FOXC2, PECAM-1, and HIF-1α whose overexpression is linked to resistance to genotoxic chemotherapy. In summary, bimetallic titanocene-gold phosphane complexes (Titanocref 2 and Titanofin 4) are very promising candidates for further preclinical evaluations for the treatment of renal cancer.

The crystal structure of (4-nitrophenyl) (5-ferrocenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl) methanone, C21H12F3FeN3O3

C21H14F3FeN3O3, triclinic, P1̄ (no. 2), a = 7.961(3) Å, b = 11.136(4) Å, c = 11.588(4) Å, α = 76.357(10)°, β = 84.998(10)°, γ = 76.989(10)° V = 972.1(6) Å3, Z = 2, R gt(F) = 0.0509, wR ref(F 2) = 0.1304, T = 273(2) K.

ROS-Responsive N-Alkylaminoferrocenes for Cancer-Cell-Specific Targeting of Mitochondria

Mitochondrial membrane potential is more negative in cancer cells than in normal cells, allowing cancer targeting by delocalized lipophilic cations (DLCs). However, as the difference is rather small, these drugs affect also normal cells. Now a concept of pro-DLCs is proposed based on an N-alkylaminoferrocene structure. These prodrugs are activated by the reaction with reactive oxygen species (ROS) forming ferrocenium-based DLCs. Since ROS are overproduced in cancer, the high-efficiency cancer-cell-specific targeting of mitochondria could be achieved as demonstrated by fluorescence microscopy in combination with two fluorogenic pro-DLCs in vitro and in vivo. We prepared a conjugate of another pro-DLC with a clinically approved drug carboplatin and confirmed that its accumulation in mitochondria was higher than that of the free drug. This was reflected in the substantially higher anticancer effect of the conjugate.

Selective Three-Component Coupling for CO2 Chemical Fixation to Boron Guanidinato Compounds

A selective three-component coupling was employed to fix carbon dioxide to boron guanidinato compounds. The one-pot reaction of carbon dioxide, carbodiimides, and borylamines (ArNH)BC₈H₁₄ afforded the corresponding 1,2-adducts {R(H)N}C{N(Ar)}(NR)(CO₂)BC₈H₁₄. Alternatively, the reaction with p-MeOC₆H₄NC or 2,6-Me₂C₆H₃NC gave the corresponding isocyanide 1,1-adducts { i-PrHN}C{N(p-Me-C₆H₄)}(N i-Pr){CNAr}BC₈H₁₄. The molecular structures of products (2,6- i-Pr₂C₆H₃NH)BC₈H₁₄ 7, { i-Pr(H)N}C{N(p-MeC₆H₄)}(N i-Pr)(CO₂)BC₈H₁₄ 9, {Cy(H)N}C{N( p-MeC₆H₄)}(Cy)(CO₂)BC₈H₁₄ 13, and { i-PrHN}C{N( p-MeC₆H₄)}(N i-Pr){CNR″}BC₈H₁₄ (R″ = p-MeOC₆H₄, 2,6-Me₂C₆H₃) 14 and 15 were established by X-ray diffraction. Density functional theory calculations at the M05-2X level of theory revealed that CO₂ fixation and formation of the corresponding adduct is exothermic and proceeds via a nonchelate boron guanidinato intermediate.

Critical Role of Anions in Platinum(II) Precursors upon the Structural Motifs of Six-Membered Cycloplatinated N,N',N″-Triarylguanidines

The reactions of cis-[Pt(OAc)₂(DMSO)₂] with 2 equiv of sym N,N',N″-triarylguanidines, [ArN=C(NHAr)₂], in toluene under reflux condition for 8 h afforded six-membered cycloplatinated guanidines, [Pt{κ²(C,N)}(OAc){κ¹ N(ArN=C(NHAr)₂)}] [sym = symmetrical; Ar = 2-MeC₆H₄ (1) and 2,4-Me₂C₆H₃ (2)], in 82 and 84% yields, respectively. The salt metathesis reaction of 1 with 1 equiv of AgTFA in CH₂Cl₂ at room temperature (RT) afforded [Pt{κ²(C,N)}(TFA){κ¹ N(ArN=C(NHAr)₂)}] (3) in 94% yield. The reaction of cis-[Pt(TFA)₂(DMSO)₂] with 1 equiv of [ArN=C(NHAr)₂] in toluene under reflux condition for 8 h afforded six-membered cycloplatinated guanidines, [Pt{κ²(C,N)}(TFA)(DMSO)] [Ar = 2-MeC₆H₄ (4), 4-MeC₆H₄ (5), 2,4-Me₂C₆H₃ (6), and 2-(MeO)C₆H₄ (7)], in ≥73% yields. The reaction of trans-[PtCl₂(PhCN)₂] with 2 equiv of [ArN=C(NHAr)₂] in toluene under reflux condition for 48 h afforded trans-[PtCl₂{ArN=C(NHAr)₂}₂] [Ar = 2-MeC₆H₄ (8) and 2,4-Me₂C₆H₃ (9)] in 90 and 45% yields, respectively. Complexes 8 and 9 were separately refluxed in MeOH for 8 h to afford six-membered cycloplatinated guanidines, [Pt{κ²(C,N)}(μ-Cl)]₂ (10 and 11), in 93 and 96% yields, respectively, with concomitant formation of the respective guanidinium salts, [(ArNH)₃C]Cl, as the byproduct. Platinacycle 10 was treated with 2 equiv of AgTFA in CH₂Cl₂ at RT to afford six-membered cycloplatinated guanidine, [Pt{κ²(C,N)}(μ-TFA)]₂ (12), in 94% yield. The new compounds were characterized by analytical techniques and multinuclear NMR (¹H, ¹³C, and ¹⁹⁵Pt) spectroscopy, and further, molecular structures of 10 compounds were determined by single-crystal X-ray diffraction. The structural motif in 1·1/2CH₂Cl₂ and 3 is novel in that it contains a planar six-membered [Pt{κ²(C,N)}] unit and a nonplanar eight-membered [Pt{κ²(N,O)}] ring, wherein OAc and the guanidine ligands are linked through a N-H···O hydrogen bond. The six-membered cycloplatinated structural motifs present in 10/11·C₇H₈ and 12·CH₂Cl₂ are also unprecedented in the literature. The number and nature of solution species of new complexes were unambiguously investigated by detailed NMR studies. The critical role of anions in Pt(II) precursors upon the course of cycloplatination and thus the motifs in the products were addressed. Plausible mechanisms of cycloplatination reactions are discussed.

A heterometallic ruthenium-gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer

Heterobimetallic compounds are designed to harness chemotherapeutic traits of distinct metal species into a single molecule. The ruthenium-gold (Ru-Au) family of compounds based on Au-N-heterocyclic carbene (NHC) fragments [Cl2(p-cymene)Ru(μ-dppm)Au(NHC)]ClO4 was conceived to combine the known antiproliferative and cytotoxic properties of Au-NHC-based compounds and the antimigratory, antimetastatic, and antiangiogenic characteristic of specific Ru-based compounds. Following recent studies of the anticancer efficacies of these Ru-Au-NHC complexes with promising potential as chemotherapeutics against colorectal, and renal cancers in vitro, we report here on the mechanism of a selected compound, [Cl2(p-cymene)Ru(μ-dppm)Au(IMes)]ClO4 (RANCE-1, 1). The studies were carried out in vitro using a human clear cell renal carcinoma cell line (Caki-1). These studies indicate that bimetallic compound RANCE-1 (1) is significantly more cytotoxic than the Ru (2) or Au (3) monometallic derivatives. RANCE-1 significantly inhibits migration, invasion, and angiogenesis, which are essential for metastasis. RANCE-1 was found to disturb pericellular proteolysis by inhibiting cathepsins, and the metalloproteases MMP and ADAM which play key roles in the etiopathogenesis of cancer. RANCE-1 also inhibits the mitochondrial protein TrxR that is often overexpressed in cancer cells and facilitates apoptosis evasion. We found that while auranofin perturbed migration and invasion to similar degrees as RANCE-1 (1) in Caki-1 renal cancer cells, RANCE-1 (1) inhibited antiangiogenic formation and VEGF expression. We found that auranofin and RANCE-1 (1) have distinct proteolytic profiles. In summary, RANCE-1 constitutes a very promising candidate for further preclinical evaluations in renal cancer.

New selenosteroids as antiproliferative agents

Starting from natural steroids (diosgenin, hecogenin, smilagenin, estrone), we have prepared a wide panel of selenoderivatives, including benzoselenazolones, selenosemicarbazones, isoselenocyanates, selenoureas, selenocyanates and diselenides, with the aim of developing new families of potential chemotherapeutic agents. The modification of the organoselenium moieties, and their position on the steroid provided valuable information concerning the antiproliferative activities. Among all the families accessed herein, the best profile was achieved for selenoureas on the A ring of estrone, which exhibited GI₅₀ values in the range 2.0-4.1 μM for all the tested tumor cell lines, with increased potency compared with commonly used chemotherapeutic agents, like 5-fluorouracil and cisplatin. Cell cycle analysis revealed that selenoureas induced accumulation of cells in the G₁ phase of the cell cycle in the breast cancer cell lines HBL-100 and T-47D; therefore, a different mechanism than cisplatin, that induces cell cycle accumulation in the S phase as a result of DNA damage, must be involved. In the rest of the tumor cells, a slight increase of the S compartment was observed. Moreover, selenosteoids turned out to be excellent glutathione peroxidase (GPx) mimics for the catalytic removal of deleterious H₂O₂ (t_1/2 8.0-22.5 min) and alkyl peroxides (t_1/2 23.0-38.9 min) when used in substoichiometric amounts (1% molar ratio), thus providing a valuable tool for reducing the intrinsic oxidative stress in tumor progression.

Chalcogen-containing phenolics as antiproliferative agents

Aim: The increasing number of cancer cases has stimulated researchers to seek for novel approaches. We have combined two bioactive moieties: a polyphenolic scaffold and an organoselenium motif. Four different families (isothiocyanates/thioureas, and their selenium isosters) derived from dopamine, (±)-norepinephrine and R-epinephrine were accessed. Results: Heterocumulenes derived from dopamine and β-O-methylnoradrenaline were strong antiproliferative agents (GI50<10 μM). Selenoureas derived from β-O-methylnoradrenaline bearing electron-withdrawing groups (halogen, -NO2, -Ph) on the phenyl ring, were also strong antiproliferative agents, besides exhibiting good antiradical and glutathione peroxidase-like activities. Up to a 14-fold increased activity was achieved compared with classical chemotherapeutic agents, exhibiting also different mechanisms of action (cell cycle assays). Redox analysis on HeLa cells suggested an increase of ROS levels after the incubation period. Conclusion: the combination of organoselenium and phenolic moieties might provide valuable lead compounds with relevant antiproliferative properties.

Research progress in modern structure of platinum complexes

Since the antitumor activity of cisplatin was discovered in 1967 by Rosenberg, platinum-based anticancer drugs have played an important role in chemotherapy in clinic. Nevertheless, platinum anticancer drugs also have caused severe side effects and cross drug resistance which limited their applications. Therefore, a significant amount of efforts have been devoted to developing new platinum-based anticancer agents with equal or higher antitumor activity but lower toxicity. Until now, a large number of platinum-based complexes have been prepared and extensively investigated in vitro and in vivo. Among them, some platinum-based complexes revealing excellent anticancer activity showed the potential to be developed as novel type of anticancer agents. In this account, we present such platinum-based anticancer complexes which owning various types of ligands, such as, amine carrier ligands, leaving groups, reactive molecule, steric hindrance groups, non-covalently binding platinum (II) complexes, Platinum(IV) complexes and polynuclear platinum complexes. Overall, platinum-based anticancer complexes reported recently years upon modern structure are emphasized.

Insertion reactions of small unsaturated molecules in the N-B bonds of boron guanidinates

We report here 1,1- and 1,2-insertion reactions of small unsaturated molecules in the N-B bonds of two boron guanidinates, (Me₂N)C(NⁱPr)₂BCy₂ (1) and {ⁱPr(H)N}C(NⁱPr){N(p-^tBu-C₆H₄)}BCy₂ (2), and two bisboron guanidinates(2-), {ⁱPr(BCy₂)N}C(NⁱPr){N(p-^tBu-C₆H₄)}BCy₂ (3) and {ⁱPr(C₈H₁₄B)N}C(NⁱPr){N(p-Me-C₆H₄)}BC₈H₁₄ (4), the latter being prepared for the first time by double deprotonation of the corresponding guanidine with the 9-borabicyclo[3.3.1]nonane dimer, (H-BC₈H₁₄)₂. Compounds 1-4 easily insert aromatic isonitriles, XylNC (Xyl = 2,6-Me₂-C₆H₃) and (p-MeO-C₆H₄)NC, to give the expected diazaboroles 5-12, some of them being structurally characterised by X-ray diffraction. Interestingly, the BC₈H₁₄ derivatives 11 and 12 are in a fast temperature-dependent equilibrium with the de-insertion products, whose thermodynamic parameters are reported here. A correlation between these equilibria and the puckered heterocyclic structure found in the solid state for 11, and confirmed by DFT calculations, is also established. Reactions of the aforementioned guanidinates with CO are more sluggish or even precluded, and only one product, {ⁱPr(H)N}C{N(p-^tBu-C₆H₄)}(NⁱPr)(CO)BCy₂ (13), could be isolated in moderate yields. The 1,2-insertions of benzaldehyde in compounds 1, 2 and 4 are reversible reactions in all cases, and only one of the insertion products, {ⁱPr(H)N}C{N(p-^tBu-C₆H₄)}(NⁱPr)(PhHCO)BCy₂ (16a), was isolated and diffractrometrically characterised. Likewise, CO₂ reversibly inserts into a N-B bond of 2 to give {ⁱPr(H)N}C{N(p-^tBu-C₆H₄)}(NⁱPr)(CO₂)BCy₂ (19) with a conversion of ca. 9%. In all these equilibria, de-insertion is always favoured upon increasing the temperature.

New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents

We have designed a series of tacrine-based homo- and heterodimers that incorporate an antioxidant tether (selenoureido, chalcogenide) as new dual compounds: for the treatment of Alzheimer's disease and as antiproliferative agents. Symmetrical homodimers bearing a dichalcogenide or selenide-based tether, the best compounds in the series, were found to be strong and highly selective electric eel AChE inhibitors, with inhibition constants within the low nanomolar range. This high inhibitory activity was confirmed on recombinant human AChE for the most interesting derivatives. The three most promising homodimers also showed a good inhibitory activity towards amyloid-β self aggregation. The symmetric disulfide derivative bis[5-(1',2',3',4'-tetrahydroacridin-9'-ylamino)pentyl]disulfide (19) showed the best multipotent profile and was not neurotoxic on immortalized mouse cortical neurons even at 50 μM concentration. These results represent an improvement in activity and selectivity compared to parent tacrine, the first marketed drug against Alzheimer's disease. Title compounds also exhibited excellent in vitro antiproliferative activities against a panel of 6 human tumor cell lines, with GI₅₀ values within the submicromolar range for the most potent derivatives (0.12-0.95 μM); such values represent a spectacular increase compared to currently-used chemotherapeutic agents, such as 5-FU (up to 306-fold) and cisplatin (up to 162-fold). Cell cycle experiments indicated the accumulation of cells in the G₁ phase of the cycle, a different mechanism than the reported for cisplatin. The breast cancer cell lines turned out to be the most sensitive one of the panel tested.

Synthesis and structural characterization of electrochemically reversible bisferrocenes containing bis(acyl-thiourea)s: enantiomers and conformers

Enantiomeric and conformational isomers of chiral bisferrocenyl-modified bis(acyl-thiourea)s; their crystal packing and electrochemically reversible redox reaction properties.

Simple ZnEt2as a catalyst in carbodiimide hydroalkynylation: structural and mechanistic studies

Simple ZnEt₂is an efficient catalyst for the addition of terminal alkynes to carbodiimides, through amidinate complexes, and consecutive isocyanate addition and intramolecular cyclohydroamination.

Tris(pentafluorophenyl)borane as an efficient catalyst in the guanylation reaction of amines

Tris(pentafluorophenyl)borane, [B(C6F5)3], has been used as an efficient catalyst in the guanylation reaction of amines with carbodiimide under mild conditions. A combined approach involving NMR spectroscopy and DFT calculations was employed to gain a better insight into the mechanistic features of this process. The results allowed us to propose a new Lewis acid-assisted Brønsted acidic pathway for the guanylation reaction. The process starts with the interaction of tris(pentafluorphenyl)borane and the amine to form the corresponding adduct, [(C6F5)3B-NRH2] , followed by a straightforward proton transfer to one of the nitrogen atoms of the carbodiimide, (i)PrN[double bond, length as m-dash]C[double bond, length as m-dash]N(i)Pr, to produce, in two consequent steps, a guanidine-borane adduct, [(C6F5)3B-NRC(N(i)PrH)2] . The rupture of this adduct liberates the guanidine product RNC(N(i)PrH)2 and interaction with additional amine restarts the catalytic cycle. DFT studies have been carried out in order to study the thermodynamic characteristics of the proposed pathway. Significant borane adducts with amines and guanidines have been isolated and characterized by multinuclear NMR in order to study the N-B interaction and to propose the existence of possible Frustrated Lewis Pairs. Additionally, the molecular structures of significant components of the catalytic cycle, namely 4-tert-butylaniline-[B(C6F5)3] adduct and both free and [B(C6F5)3]-bonded 1-(phenyl)-2,3-diisopropylguanidine, and respectively, have been established by X-ray diffraction.

Dialkylboron guanidinates: syntheses, structures and carbodiimide de-insertion reactions

Solutions of some of the title compounds reached an equilibrium with the aminoboranes and the corresponding carbodiimides at room temperature.